An open label, sequential cohort dose-escalation safety, tolerability and pharmacokinetic study of VEGF [vascular endothelial growth factor] trap [aflibercept] administered intravenously in patients with advanced solid tumors or lymphoma
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Aflibercept (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 09 Jan 2007 New trial record.